On March 25, the FDA has approved relacorilant (Lifyorli), in combination with nab-paclitaxel for adults with platinum-resistant ovarian and related gynecologic cancers who have received prior systemic...
Stay up to date with the evolving standards of breast cancer care — our new timeline snapshot highlights the most significant U.S. clinical guideline changes from 2024 to present, including updates from...
A longitudinal analysis from the Western Australian Raine Study evaluated whether polycystic ovary syndrome coexisting with metabolic dysfunction–associated steatotic liver disease during adolescence is...
A phase 2 nonrandomized clinical trial explored whether breast surgery could be safely eliminated for women with ERBB2-positive or triple-negative invasive breast cancer who achieved a pathologic complete...
A randomized trial in breast cancer survivors found that just one session of resistance or high-intensity interval training significantly elevated circulating anti-cancer myokines and reduced the growth of...
The phase 3 SERENA-6 trial evaluated whether replacing an aromatase inhibitor with camizestrant while continuing a CDK4/6 inhibitor in patients with ER-positive, HER2-negative advanced breast cancer and...
In a large multicenter randomized trial, intrapartum oral sildenafil citrate did not reduce adverse perinatal outcomes related to fetal hypoxia compared with placebo.
In women with dense breast tissue and a negative screening mammogram, abbreviated MRI and contrast-enhanced mammography tripled the detection rate of invasive breast cancer compared with automated breast...
A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be linked to longer progression-free survival in...
The 2025 American Society of Clinical Oncology guideline update redefines the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. Building on evidence from major trials, the update...
